Imraldi®

ACTIVE PRINCIPLE:
adalimumab

INDICATION:
Ankylosing spondylitis
Arthritis
Uveitis
Rheumatoid Arthritis
Hidradenitis suppurativa
Ulcerative colitis
Psoriasic arthritis
Crohn's disease
Psoriasis

DATE:
25/05/2018

STATUS:
Authorized

MORE INFORMATION